Michael J. Fox Foundation and New York Academy of Sciences to Host First Major Parkinson's Drug Development Conference
The conference will bring together academic and industry scientists to assess and discuss how novel scientific advances can be applied to accelerate the development of innovative drug discovery approaches to Parkinson’s disease. Select MJFF-funded investigators will present research on topics including novel neuroprotective agents, innovative mechanisms to address disease symptoms and improvements in relevant animal models, and biomarker discovery/development.
“The PD Therapeutics Conference will feature the latest updates on ongoing research, as well as highlight new studies and concepts,” said conference chair C. Warren Olanow, MD, the Henry P. and Georgette Goldschmidt Professor and Chairman of the Department of Neurology and Professor of Neuroscience at the Mount Sinai School of Medicine in New York City, as well as Chief of the Neurology Service at the Mount Sinai Hospital. “Our primary objectives for the conference are twofold: to discuss scientific progress on drug discovery initiatives aimed at better treating Parkinson’s disease, and to provide a new networking opportunity for scientists to share information and resources.”
The conference, targeted toward a multidisciplinary network of academic, pharmaceutical and biotechnology industry researchers, is expected to attract over 100 attendees from around the globe. Due to limited space, registration priority will be given to scientists whose research priority is PD or an allied neuroscience discipline.
The meeting will be held at The New York Academy of Sciences Conference Center, 7
Leadership funding for the PD Therapeutics Conference has been provided by Elan Corporation, plc (NYSE: